Markets were strong on Monday on the news that a proposed vaccine has achieved a 94.5% success rate so far in a Phase III clinical trial. And this one does not require ultra cold storage in distribution. While it would be some months before the vacc...
Members only content
The content on this page is for members only. If you are a member, log in below. If you are not a member, please Register.